Related Experiment Videos
Does acyclovir increase serum lithium levels?
R K Sylvester1, J Leitch, C Granum
1MeritCare Hospital, North Dakota State University, Fargo 58105, USA.
Pharmacotherapy
|May 1, 1996
Summary
Intravenous acyclovir may increase lithium levels in patients, potentially causing toxicity. Healthcare providers should monitor lithium levels closely during concurrent acyclovir therapy.
Area of Science:
- Nephrology
- Pharmacology
- Infectious Diseases
Background:
- Lithium carbonate is a common mood stabilizer requiring careful monitoring due to its narrow therapeutic index.
- Herpes zoster infections are often treated with antiviral medications like acyclovir.
- Both lithium and acyclovir are renally excreted, suggesting potential pharmacokinetic interactions.
Observation:
- A patient receiving lithium carbonate developed signs of lithium toxicity after initiating intravenous acyclovir therapy.
- Serum lithium levels increased fourfold during the course of acyclovir administration.
- No prior literature documented an interaction between acyclovir and lithium.
Findings:
- High-dose intravenous acyclovir may impede the renal excretion of lithium.
- This interaction can lead to elevated serum lithium concentrations and potential toxicity.
- The mechanism may involve competition for renal clearance pathways.
Implications:
- Clinicians should exercise caution when co-administering intravenous acyclovir and lithium.
- Close monitoring of serum lithium levels and assessment for toxicity symptoms are recommended during concurrent therapy.
- Further research is warranted to elucidate the precise mechanism and clinical significance of this drug interaction.